MLXIPL and metabolic dysfunction-associated steatotic liver disease: Excess glucose and fructose metabolism, via activation of ChREBP, contributes to IRS-2 down-regulation, hyperinsulinemia reinforces it, and together they drive development of hepatic insulin resistance and MASLD.